Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 343

1.

Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study.

Carballal S, Rodríguez-Alcalde D, Moreira L, Hernández L, Rodríguez L, Rodríguez-Moranta F, Gonzalo V, Bujanda L, Bessa X, Poves C, Cubiella J, Castro I, González M, Moya E, Oquiñena S, Clofent J, Quintero E, Esteban P, Piñol V, Fernández FJ, Jover R, Cid L, López-Cerón M, Cuatrecasas M, López-Vicente J, Leoz ML, Rivero-Sánchez L, Castells A, Pellisé M, Balaguer F; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Gut. 2015 Aug 11. pii: gutjnl-2015-309647. doi: 10.1136/gutjnl-2015-309647. [Epub ahead of print]

PMID:
26264224
2.

Let-7 Represses Carcinogenesis and a Stem Cell Phenotype in the Intestine via Regulation of Hmga2.

Madison BB, Jeganathan AN, Mizuno R, Winslow MM, Castells A, Cuatrecasas M, Rustgi AK.

PLoS Genet. 2015 Aug 5;11(8):e1005408. doi: 10.1371/journal.pgen.1005408. eCollection 2015 Aug.

3.

Transanal Total Mesorectal Excision for Rectal Cancer: Outcomes after 140 Patients.

Lacy AM, Tasende MM, Delgado S, Fernandez-Hevia M, Jimenez M, De Lacy B, Castells A, Bravo R, Wexner SD, Heald RJ.

J Am Coll Surg. 2015 Aug;221(2):415-23. doi: 10.1016/j.jamcollsurg.2015.03.046. Epub 2015 Mar 30.

PMID:
26206640
4.

Endoscopic surveillance in patients with multiple (10 - 100) colorectal polyps.

Valentín F, Guarinos C, Juárez M, Rodríguez-Soler M, Serradesanferm A, Rodriguez-Moranta F, Nicolas-Perez D, Bujanda L, Herraiz M, De-Castro L, Fernández-Bañares F, Herreros-de-Tejada A, Martínez F, Aguirre E, Ferrández Á, Díaz-Tasende J, Piñol V, Paya A, Egoavil C, Alenda C, Castells A, Jover R, Cubiella J.

Endoscopy. 2015 Jul 10. [Epub ahead of print]

PMID:
26165738
5.

Choosing the optimal method in programmatic colorectal cancer screening: current evidence and controversies.

Castells A.

Therap Adv Gastroenterol. 2015 Jul;8(4):221-33. doi: 10.1177/1756283X15578610. Review.

6.

Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients.

Auge JM, Fraser CG, Rodriguez C, Roset A, Lopez-Ceron M, Grau J, Castells A, Jimenez W.

Clin Chem Lab Med. 2015 Jun 27. pii: /j/cclm.ahead-of-print/cclm-2015-0388/cclm-2015-0388.xml. doi: 10.1515/cclm-2015-0388. [Epub ahead of print]

PMID:
26124057
7.

MiR-320e is a novel prognostic biomarker in colorectal cancer.

Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A.

Br J Cancer. 2015 Jun 30;113(1):83-90. doi: 10.1038/bjc.2015.168. Epub 2015 Jun 2.

PMID:
26035698
8.

Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.

Hamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, Castells A, Llor X, Andreu M, Carethers JM.

PLoS One. 2015 May 21;10(5):e0127591. doi: 10.1371/journal.pone.0127591. eCollection 2015.

9.

A case of esophageal adenocarcinoma on long-term rapamycin monotherapy.

Canha C, Ferreira R, Rovira J, Moya-Rull D, Castells A, Diekmann F, Oppenheimer F, Campistol JM, Revuelta I.

Transpl Int. 2015 May 4. doi: 10.1111/tri.12600. [Epub ahead of print]

PMID:
25939687
10.

Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer.

Castillejo A, Hernández-Illán E, Rodriguez-Soler M, Pérez-Carbonell L, Egoavil C, Barberá VM, Castillejo MI, Guarinos C, Martínez-de-Dueñas E, Juan MJ, Sánchez-Heras AB, García-Casado Z, Ruiz-Ponte C, Brea-Fernández A, Juárez M, Bujanda L, Clofent J, Llor X, Andreu M, Castells A, Carracedo A, Alenda C, Payá A, Jover R, Soto JL.

J Med Genet. 2015 Jul;52(7):498-502. doi: 10.1136/jmedgenet-2015-103076. Epub 2015 Apr 23.

PMID:
25908759
11.

Colorectal cancer in a second round after a negative faecal immunochemical test.

Bujanda L, Sarasqueta C, Castells A, Pellisé M, Cubiella J, Gil I, Cosme A, Arana-Arri E, Mar I, Idigoras I, Portillo I; EUSCOLON Study Investigators.

Eur J Gastroenterol Hepatol. 2015 Jul;27(7):813-8. doi: 10.1097/MEG.0000000000000366.

PMID:
25856688
12.

Pitfalls in the diagnosis of biallelic PMS2 mutations.

Antelo M, Milito D, Rhees J, Roca E, Barugel M, Cuatrecasas M, Moreira L, Leoz ML, Carballal S, Ocaña T, Pellisé M, Castells A, Boland CR, Goel A, Balaguer F.

Fam Cancer. 2015 Mar 15. [Epub ahead of print]

PMID:
25773960
13.

Postoperative surveillance in nonmetastatic colorectal cancer patients: yes, but...

Castells A.

Ann Oncol. 2015 Apr;26(4):615-7. doi: 10.1093/annonc/mdv020. Epub 2015 Jan 20. No abstract available.

PMID:
25605742
14.

Clinical management of hereditary colorectal cancer syndromes.

Vasen HF, Tomlinson I, Castells A.

Nat Rev Gastroenterol Hepatol. 2015 Feb;12(2):88-97. doi: 10.1038/nrgastro.2014.229. Epub 2015 Jan 13. Review.

PMID:
25582351
15.

Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer.

Moreira L, Muñoz J, Cuatrecasas M, Quintanilla I, Leoz ML, Carballal S, Ocaña T, López-Cerón M, Pellise M, Castellví-Bel S, Jover R, Andreu M, Carracedo A, Xicola RM, Llor X, Boland CR, Goel A, Castells A, Balaguer F; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Cancer. 2015 May 1;121(9):1395-404. doi: 10.1002/cncr.29190. Epub 2014 Dec 29.

PMID:
25557234
16.

Postpolypectomy surveillance in patients with adenomas and serrated lesions: a proposal for risk stratification in the context of organized colorectal cancer-screening programs.

Castells A, Andreu M, Binefa G, Fité A, Font R, Espinàs JA.

Endoscopy. 2015 Jan;47(1):86-7. doi: 10.1055/s-0034-1378100. Epub 2014 Dec 22. No abstract available.

PMID:
25532113
17.

Programmatic screening for colorectal cancer: the COLONPREV study.

Castells A, Quintero E.

Dig Dis Sci. 2015 Mar;60(3):672-80. doi: 10.1007/s10620-014-3446-2. Epub 2014 Dec 10.

PMID:
25492501
18.

Ascorbic acid PEG-2L is superior for early morning colonoscopies in colorectal cancer screening programs: a prospective non-randomized controlled trial.

Rodríguez de Miguel C, Serradesanferm A, López-Cerón M, Carballal S, Pozo A, Balaguer F, Cárdenas A, Fernández-Esparrach G, Ginés A, González-Suárez B, Moreira L, Ordás I, Ricart E, Sendino O, Vaquero EC, Ubré M, del Manzano S, Grau J, Llach J, Castells A, Pellisé M; PROCOLON group.

Gastroenterol Hepatol. 2015 Feb;38(2):62-70. doi: 10.1016/j.gastrohep.2014.09.007. Epub 2014 Oct 29.

PMID:
25458542
19.

Diagnostic performance of fecal immunochemical test and sigmoidoscopy for advanced right-sided colorectal neoplasms.

Castro I, Estevez P, Cubiella J, Hernandez V, González-Mao C, Rivera C, Iglesias F, Cid L, Soto S, de-Castro L, Vega P, Hermo JA, Macenlle R, Martínez A, Cid E, Gil I, Larzabal M, Bujanda L, Castells A; COLONPREV study investigators.

Dig Dis Sci. 2015 May;60(5):1424-32. doi: 10.1007/s10620-014-3434-6. Epub 2014 Nov 19.

PMID:
25407805
20.

Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.

García-Albéniz X, Gallego R, Hofheinz RD, Fernández-Esparrach G, Ayuso-Colella JR, Bombí JA, Conill C, Cuatrecasas M, Delgado S, Ginés A, Miquel R, Pagés M, Pineda E, Pereira V, Sosa A, Reig O, Victoria I, Feliz L, María de Lacy A, Castells A, Burkholder I, Hochhaus A, Maurel J.

World J Gastroenterol. 2014 Nov 14;20(42):15820-9. doi: 10.3748/wjg.v20.i42.15820.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk